Jefferies Group’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-8,350
Closed -$346K 1552
2022
Q1
$346K Buy
+8,350
New +$259K ﹤0.01% 1145
2020
Q1
Sell
-3,419
Closed -$353K 2054
2019
Q4
$353K Buy
+3,419
New +$138K ﹤0.01% 2002
2019
Q2
Sell
-67,788
Closed -$965K 2515
2019
Q1
$965K Buy
+67,788
New +$629K 0.01% 1285

Other funds holding AXSM

Jefferies Group's AXSM Position: Q2 2022 in Review

Jefferies Group sold out of Axsome Therapeutics (AXSM) in Q2 2022, closing a stake of 8,350 shares — an estimated $346K sold.

Jefferies Group first reported a position in AXSM in Q1 2019 and held it in 3 quarters. The position peaked at $965K in Q1 2019. 174 funds tracked by Wall St. Rank hold AXSM as of Q2 2022.

  • Jefferies Group reported no remaining Axsome Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jefferies Group sold 8,350 Axsome Therapeutics shares in Q2 2022, an estimated $346K.
  • Jefferies Group first reported a position in Axsome Therapeutics in Q1 2019 and held it in 3 quarters.
  • Jefferies Group's Axsome Therapeutics position peaked at $965K in Q1 2019.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.